Skip to content

Trial Summary

Registry-based Study of Enzalutamide vs Abiraterone assessing cognitive function in Elderly Metastatic Castration-Resistant Prostate Cancer



ACTRN/NCT /ethics:


Scientific title:

A prospective, open-label, multi-centre, registry-based randomised clinical trial comparing the cognitive impact of standard-of-care treatments in men aged 75 years or older that have metastatic castration-resistant prostate cancer.

Sponsor / Cooperative group:

Walter & Eliza Hall Institute

Trial & Patient Characteristics

Cancer TypeProstate
Trial TypeTreatment
PhasePhase IV
Age Range75 years and older
Tumour Stream Prostate
Cancer StageMetastatic or Widespread
Anticipated Start Date2019-06-12
Anticipated End Date2022-04-26

Participating Hospitals

HospitalAshford Cancer Centre Research
Clinical Trial CoordinatorSue Yeend
Phone08 8292 2240
Principal InvestigatorDr Francis Parnis
Recruitment StatusRecruiting